BIOCEUTICALS_LIMITED - Accounts


Company Registration No. 08138589 (England and Wales)
BIOCEUTICALS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018
PAGES FOR FILING WITH REGISTRAR
BIOCEUTICALS LIMITED
COMPANY INFORMATION
Director
Mr H I A Patel
Company number
08138589
Registered office
Brandon House
and business address
Marlowe Way
Croydon
Surrey
CR0 4XS
Accountants
Silver Levene (UK) Limited
Chartered Certified Accountants
37 Warren Street
London
W1T 6AD
BIOCEUTICALS LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 6
BIOCEUTICALS LIMITED
BALANCE SHEET
AS AT 31 MARCH 2018
31 March 2018
- 1 -
2018
2017
Notes
£
£
£
£
Fixed assets
Tangible assets
3
-
1,263
Current assets
Stocks
3,970
14,984
Debtors
4
11,117
8,527
Cash at bank and in hand
12,808
16,944
27,895
40,455
Creditors: amounts falling due within one year
5
(12,248)
(71,721)
Net current assets/(liabilities)
15,647
(31,266)
Total assets less current liabilities
15,647
(30,003)
Capital and reserves
Called up share capital
6
5,100
5,100
Profit and loss reserves
10,547
(35,103)
Total equity
15,647
(30,003)

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 March 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and signed by the director and authorised for issue on 13 February 2019
Mr H I A Patel
Director
Company Registration No. 08138589
BIOCEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2018
- 2 -
1
Accounting policies
Company information

Bioceuticals Limited is a private company limited by shares incorporated in England and Wales. The registered office is Brandon House, Marlowe Way, Croydon, Surrey, CR0 4XS.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

At the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.

1.3
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Tangible fixed assets are stated at cost less depreciation. Website development costs are capitalised as plant and machinery.  Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:
Plant and machinery
20% straight line
Fixtures, fittings & equipment
20% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

BIOCEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2018
1
Accounting policies
(Continued)
- 3 -
1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

BIOCEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2018
1
Accounting policies
(Continued)
- 4 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 1 (2017 - 1).

BIOCEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2018
- 5 -
3
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 April 2017 and 31 March 2018
18,179
Depreciation and impairment
At 1 April 2017
16,916
Depreciation charged in the year
1,263
At 31 March 2018
18,179
Carrying amount
At 31 March 2018
-
At 31 March 2017
1,263
4
Debtors
2018
2017
Amounts falling due within one year:
£
£
Trade debtors
9,767
7,177
Other debtors
1,350
1,350
11,117
8,527
5
Creditors: amounts falling due within one year
2018
2017
£
£
Trade creditors
4,548
5,252
Amounts owed to group undertakings
1,121
53,216
Taxation and social security
4,079
6,253
Other creditors
2,500
7,000
12,248
71,721

Amounts due to group undertakings are unsecured, interest free and repayable on demand.

BIOCEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 MARCH 2018
- 6 -
6
Called up share capital
2018
2017
£
£
Ordinary share capital
Issued and fully paid
5,000 Ordinary shares of £1 each
5,000
5,000
10,000 Ordinary A shares of 1p each
100
100
5,100
5,100
7
Related party transactions

The company has taken advantage of the exemption provided in FRS 102 Section 1A from disclosing transactions with members of the same group that are wholly owned.

2018-03-312017-04-01falseCCH SoftwareCCH Accounts Production 2018.300No description of principal activity14 February 2019Mr H I A Patel081385892017-04-012018-03-3108138589bus:Director32017-04-012018-03-3108138589bus:Director12017-04-012018-03-3108138589bus:RegisteredOffice2017-04-012018-03-31081385892018-03-31081385892017-03-3108138589core:OtherPropertyPlantEquipment2017-03-3108138589core:CurrentFinancialInstruments2018-03-3108138589core:CurrentFinancialInstruments2017-03-3108138589core:ShareCapital2018-03-3108138589core:ShareCapital2017-03-3108138589core:RetainedEarningsAccumulatedLosses2018-03-3108138589core:RetainedEarningsAccumulatedLosses2017-03-3108138589core:ShareCapitalOrdinaryShares2018-03-3108138589core:ShareCapitalOrdinaryShares2017-03-3108138589core:PlantMachinery2017-04-012018-03-3108138589core:FurnitureFittings2017-04-012018-03-3108138589core:OtherPropertyPlantEquipment2017-03-3108138589core:OtherPropertyPlantEquipment2018-03-3108138589core:OtherPropertyPlantEquipment2017-04-012018-03-3108138589bus:OrdinaryShareClass12017-04-012018-03-3108138589bus:OrdinaryShareClass22017-04-012018-03-3108138589bus:OrdinaryShareClass12018-03-3108138589bus:OrdinaryShareClass22018-03-3108138589bus:PrivateLimitedCompanyLtd2017-04-012018-03-3108138589bus:FRS1022017-04-012018-03-3108138589bus:AuditExemptWithAccountantsReport2017-04-012018-03-3108138589bus:SmallCompaniesRegimeForAccounts2017-04-012018-03-3108138589bus:FullAccounts2017-04-012018-03-31xbrli:purexbrli:sharesiso4217:GBP